ReviewEuropean journal of cell biology2022
Fixing the GAP: The role of RhoGAPs in cancer.
Review in European journal of cell biology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 32 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
32 citing papers in PubMed, 55 citations in OpenAlex.
- Rho GTPases in cancer resistance: mechanisms, vulnerabilities, and therapeutic opportunities.Biochemical Society transactions · 2026Review
- Decoding Rho GTPase signalling networks in directed cell migration.Frontiers in cell and developmental biology · 2026Review
- Systematic Evaluation of GAPs and GEFs Identifies a Targetable Dependency for Hematopoietic Malignancies.Cancer discovery · 2025Article
- ARHGAP11A, a member of Rho GTPase activating protein family, as a prognostic biomarker linked to DNA damage response across pan-cancer.BMC cancer · 2025Article
- Control of stress-activated Cdc42 dynamics by the MAP kinase Sty1-NDR kinase Orb6 regulatory axis.iScience · 2025Article
- ARHGAP4/MYH9/β-catenin/c-Jun positive feedback loop promotes colorectal cancer stemness.NPJ precision oncology · 2025Article
- Identification of clusters related to programmed cell death and potential prognostic biomarkers for immunotherapy response in endometrial cancer.Scientific reports · 2025Article
- Article
- Understanding the Role of Rho GTPase Activating Protein and Bone Marrow Kinase X: A Novel Target in Gastric Cancer Treatment.Asian Pacific journal of cancer prevention : APJCP · 2025Review
- Specific effects of hypoxia-immune core geneTranslational cancer research · 2025Article
- β2-Chimaerin Deficiency Favors Polyp Growth in the Colon of ApcMolecules (Basel, Switzerland) · 2025Article
- Medwakh smoking induces alterations in salivary proteins and cytokine expression: a clinical exploratory proteomics investigation.Clinical proteomics · 2025Article
- Dynamic Coupling of MAPK Signaling to the Guanine Nucleotide Exchange Factor GEF-H1.OncoTargets and therapy · 2025Review
- Loss of Arhgap39 facilitates cell migration and invasion in murine hepatocellular cancer cells.Oncology research · 2025Article
- Integrated analysis of ARHGAP6 potential function and prognostic value in acute myeloid leukemia.PloS one · 2025Article
- An allosteric inhibitor of RhoGAP class-IX myosins suppresses the metastatic features of cancer cells.Nature communications · 2024Article
- RhoJ: an emerging biomarker and target in cancer research and treatment.Cancer gene therapy · 2024Review
- Molecular mechanism of bitter taste receptor agonist-mediated relaxation of airway smooth muscle.FASEB journal : official publication of the Federation of American Societies for Experimental Biology · 2024Article
- Elevated expression of wildtype RhoC promotes ErbB2- and Pik3ca-induced mammary tumor formation.Breast cancer research : BCR · 2024Article
- RACGAP1 knockdown synergizes and enhances the effects of chemotherapeutics on ovarian cancer.American journal of translational research · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 1 institution in 1 country.
Funding
Abstract
Cancer progression and metastasis are processes that involve significant cellular changes. Many of these changes include alterations in the activity of the Rho GTPase family of proteins. Rho GTPases are signaling proteins that function as molecular switches and are involved in the regulation of most major cellular processes. Cancer development is often associated with abnormalities in Rho GTPase signaling. Rho GTPase signaling is regulated by two families of proteins, guanine nucleotide-exchange factors (RhoGEFs) and GTPase activating proteins (RhoGAPs), that function upstream of the Rho proteins to regulate their activation and inactivation, respectively. While initial work has focused on the role of RhoGEFs in cancer, the RhoGAP family members are rapidly being established as key regulators of cancer development and progression. The aim of this review is to summarize our advances in understanding the role of RhoGAPs in cancer and to discuss their significance in the development of therapeutics.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.